Importance of marrow dose on posttransplant outcome in acute leukemia: Models derived from patients autografted with mafosfamide-purged marrow at a single institution

Experimental Hematology

Volumn 27, Issue 12, 1999, Pages 1822-1830

  Gorin, Norbert Claude ^a   Labopin, Myriam ^a   Laporte, Jean Philippe ^a   Douay, Luc ^b   Lopez, Manuel ^a   Lesage, Sylvie ^a   Fouillard, Loïc ^a   Isnard, Françoise ^a   Jouet, Jean Pierre ^c   Bellal, Nassima ^a   Perot, Christine ^a   Van Den Akker, Jacqueline ^a   Bauters, Francis ^c   Najman, Albert ^c  

^a HÔPITAL SAINT ANTOINE   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute leukemia; Autologous bone marrow transplantation; Dose of stem cells; Purging in vivo with mafosfamide

Indexed keywords

CYCLOPHOSPHAMIDE; MAFOSFAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CLINICAL TRIAL; CYTOGENETICS; FEMALE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; TECHNIQUE; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CELL COUNT; CHILD; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0032730253     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00121-6     Document Type: Article

References (56)

1. Gorin N.C., Najman A., Duhamel G. Autologous bone marrow transplantation in acute myelocytic leukemia. Lancet. 1:1977;1050.
2. Appelbaum F.R., Herzig G.P., Ziegler J.L., Graw R.G.G., Levine A.S., Deisseroth A.B. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood. 52:1978;85.
3. Dicke K.A., Sptizer G., Peters L., Mac Credie K.C., Zander A., Verma D.S., Vellekoop L., Hester J. Autologous bone marrow transplantation in relapsed adult acute leukemia. Lancet. 1:1979;514.
4. Gorin NC (1998) Autologous stem cell transplantation in acute myelocytic leukemia. Blood 92:/1073.
5. Korbling M, Hunstein W, Fliedner TM, Cayeux S, Dorken B, Fehrentz D, Haas R, Ho AD, Keilholz U, Kneuf W, Konig A, Mende U, PezWolf G, Kzuto A, Wannenmacher M, zum Winkel K, Rother K (1989) Disease free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood 74:1898.
6. Cassileth P.A., Andersen J., Lazarus H.M., Colvin O.M., Bennett J.M., Stadtmauer E.A., Kaizer H., Weiner R.S., Edelstein M., Oken M.M. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 11:1993;314.
7. Linker C.A., Ries C.A., Damon L.E., Rugo H.S., Wolf J.L. Autologous bone marrow transplantation for acute myeloid leukemia using 4 hydroperoxycyclosphosphamide purged bone marrow and the busulfan-etoposide preparative regimen. a follow up report Bone Marrow Transplant. 22:1998;865.
8. Gorin N.C., Douay L., Laporte J.P., Lopez M., Mary J.Y., Najman A., Salmon C., Aegerter P., Stachowiak J., David R., Pene F., Kankor G., Deloux J., Duhamel E., Van Der Akker J., Gerota Y., Parker Y., Duhamel G. Autologous bone marrow transplantation using marrow incubated with ASTA-Z 7557 in adult acute leukemia. Blood. 67:1986;1367.
9. Laporte J.P., Douay L., Lopez M., Labopin M., Jouet J.P., Lesage S., Stachowiak J., Fouillard L., Isnard F., Noel-Walter M.P., Pene F., Deloux J., Van Den Akker J., Grande M., Bauters F., Najman A., Gorin N.C. One hundred twenty five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide. A 10 year single institution experience. Blood. 84:1994;3810.
10. Gulati S., Acaba L., Yalahom J., Reich L., Motzer R., Crown J., Doherty M., Clarkson B., Berman E., Atzpodien J., Andreeff M., Gee T. Autologous bone marrow transplantation for acute myelogenous leukemia, using 4 hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant. 10:1992;129.
11. Selvaggi K.J., Wilson J.W., Mills L.E., Corwell G.G., Hurd D., Dodge W., Gingrich R., Martin S.E., McMillan R., Miller W.et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood. 83:1994;1698.
12. Yeager A.M., Kaizer H., Santos G.W., Saral R., Colvin O.N., Stuart R.K., Brain H.G., Burke P.J., Ambinder R.F., Burns W.H., Fuller D.J., David J.M., Karp J.E., May W.S., Rowley S.D., Sensenbrenner L.L., Vogelsang G.B., Wingard J.R. Autulogous bone marrow transplantation in patients with acute non lymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 315:1986;141.
13. Carella A.M., Gaozza E., Santini G., Martinengo M., Pungolino E., Piatti G., Congiu A., Nati S., Carlier P., Giordano D., Cerri R., Risso M., Miceli S., Raffo M.R., Scarpati D., Corvo R., Franzone P., Vitale V., Vimercati A.R., D'Amico T., Maromont A. Autologous unpurged bone marrow transplantation for acute non lymphoblastic leukaemia in first remission. Bone Marrow Transplant. 3:1988;537.
14. Dicke K., Jagannath S., Walters R.S., Horwitz L.J., Spitzer G. The role of autologous bone marrow transplantation in acute leukemia. Ann N Y Acad Sci. 511:1987;468.
15. Mc Millan A.K., Goldstone A.H., Linch D.C., Gribben J.G., Patterson K.G., Richards J.D.M., Franklin I., Boughton B.J., Milligan D.W., Leyland M., Hutchison R.M., Newland A.C. High dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood. 76:1990;480.
16. Stein A.S., O'Donnell M.R., Chai A., Schmidt G.M., Nademanee A., Parker P.M., Smith E.P., Snyder D.S., Molina A., Stepan D.E., Spielberger R., Somlo G., Margolin K.A., Vora N., Lipsett J., Lee J., Niland J., Forman S.J. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol. 14:1996;2206.
17. Meloni G., De Fabritiis P., Carella A.M., Mangoni L., Porcellini A., Marmont A., Mandelli F. Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy. Bone Marrow Transplant. 5:1990;29.
18. Sierra J., Granena A., Garcia J., Valls A., Carreras E., Rovira M., Canals C., Martinez E., Punti C., Algara M.et al. Autologous bone marrow transplantation for acute leukemia. results and prognostic factors in 90 consecutive patients Bone Marrow Transplant. 12:1993;517.
19. Mehta J., Powles R., Singhal S., Horton C., Tait D., Milan S., Meller S., Pinkerton C.R., Treleaven J. Autologous bone marrow transplantation for acute myeloid leukemia in first remission. identification of modifiable prognostic factors Bone Marrow Transplant. 16:1995;499.
20. Miggiano M.C., Gherlinzoni F., Rosti G., Bandini G., Fiacchini M., Ricci P., Testoni N., Motta M.R., Geromin A., Rizzi S., Belardinelli A., Mangianti S., Manfroi S., Tura S. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia. 10:1996;402.
21. Rizzoli V., Carlo-Stella C. Stem cell purging. an intriguing dilemma Exp Hematol. 23:1995;296.
22. Zittoun R.A., Mandelli F., Willemze R., de Witte T., Labar B., Resegotti L., Leoni F., Damasio E., Visani G., Papa G.et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 332:1995;217.
23. Burnett A.K., Goldstone A.H., Stevens R.M.F., Hann I.M., Gray R.G., Rees J.K.H., Wheatley K.W. Randomised comparison of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission. results of MRC-AML 10 trial Lancet. 351:1998;700.
24. Sierra J., Brunet S., Granena A., Olive T., Bueno J., Ribera J.M., Petit J., Besses C., Liorentae A., Guardia R., Macia J., Rovira M., Badel I., Vela E., Diaz De Heredia C., Vivancos P., Carreras E., Feliu E., Montserrat E., Julia A., Cubells J., Rozman C., Domingo A., Ortega J.J. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan group for bone marrow transplantation. J Clin Oncol. 14:1996;1353.
25. Suciu S, on behalf of the AML collaborative group of EORTC (1998) Meta-analysis of randomized trials comparing autologous BMT (ABMT) vs chemotherapy (CT) or ABMT vs no further treatment (NFT) as post remission treatment in adult AML patients. Bone Marrow Transplant 21:43a.
26. Sharkis S.J., Santos G.W., Colvin O.M. Elimination of acute myelogenous leukemia cells from marrow and tumor suspensions in the rat with 4 hydroperoxycyclophosphamide. Blood. 55:1980;521.
27. Wiley JM, Yeager AM (1991) Predictive value of colony forming unit assays for engraftment and leukemia free survival after transplantation of chemopurged syngeneic bone marrow in rats: Exp Hematol 19:179.
28. Gorin N.C., Aegerter P., Auvert B., Meloni G., Goldstone A.H., Burnett A., Carella A., Korbling M., Herve P., Maraninchi D., Lowenberg R., Verdonck L.F., De Planque M., Hermans J., Helbig W., Porcellini A., Rizzoli V., Alesandrino E.P., Franklin I.M., Reiffers J., Colleselli P., Goldman J.M. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission. a European survey of the role of marrow purging Blood. 75:1990;1606.
29. Gorin N.C., Labopin M., Meloni G., Korbling M., Carella A., Herve P., Burnett A., Rizzoli V., Alessandrino E.P., Bjorkstrand B., Ferrant A., Lowenberg B., Coser P., Simonsson B., Helbig W., Brunet Mauri S., Verdonck L.F., Iriondo A., Polli E., Colombat P., Franklin I.M., Souillet G., Willemze R. Autologous bone marrow transplantation for acute myelocytic leukemia in Europe. further evidence of the role of marrow purging by mafosfamide Leukemia. 5:1991;896.
30. Miller CB, Smith D, Horowitz MM, Lazarus HM, Jones RJ (1998) Autologous stem cell transplant in acute myelogenous leukemia after relapse. Ninth International Symposium on Autologous Blood and Marrow Transplant (unpublished).
31. Brenner M.K., Rill D.R., Moen R.C., Krance R.A., Mirro J. Jr., Anderson W.F., Ihle J.N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85.
32. Deisseroth A.B., Zu Z., Claxton D., Hanania E.G., Fu S., Ellerson D., Goldberg L., Thomas M., Janicek K., Anderson F., Hester J., Korbling M., Durett A., Moen R., Berenson R., Heimfeld S., Harmer J., Calvert L., Tibbits P., Talpaz M., Kantarjian H., Champlin R., Reading C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood. 83:1994;3068.
33. Lopez M., Dupuy-Montbrun M.C., Douay L., Laporte J.P., Gorin N.C. Standardization and characterization of the procedure for in vitro treatment of human bone marrow with cyclophosphamide derivatives. Clin Lab Haematol. 7:1985;327.
34. Douay L., Mary J.Y., Giarratana M.C., Najman A., Gorin N.C. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (Asta Z 7557). Exp Hematol. 17:1989;429.
35. Douay L., Giarratana M.C., Labopin M.et al. Characterization of late and early hematopoietic progenitor stem cell sensitivity to mafosfamide. Bone Marrow Transplant. 15:1995;769.
36. Douay L., Gorin N.C., Laporte J.P., Lopez M., Najman A., Duhamel G. Asta Z 7557 (INN Mafosfamide) for the in vitro treatment of human leukemic marrow. Invest New Drugs. 2:1984;187.
37. Gorin N.C. Collection, manipulation and freezing of haemopoietic stem cells. Clin Haematol. 15:1986;19.
38. Pike B.L., Robinson W.A. Human bone marrow colony growth in Agar gel. J Cell Physiol. 76:1970;77.
39. Schlunk T., Schleyer M. The influence of culture conditions on the production of colony stimulating activity by human placenta. Exp Hematol. 8:1980;179.
40. Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
41. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187.
42. Byar DP (1988) Identification of prognostic factors. In: Buyse ME, Staquer MJ, Sylvester RJ (eds.) Cancer clinical trials methods and practice. Oxford Medical Publications, pp. 423-443.
43. Rowley S.D. Pharmacological purging of malignant cells. Forman S.J., Blume K.G., Thomas E.D. Bone marrow transplant. 1995;Blackwell Scientific Publications, Boston. 164-178pp.
44. Gribben J.G., Nadler L.M. Bone marrow purging for autologous bone marrow transplantation. Leuk Lymphoma. 11:1993;141.
45. Billett A.L., Sallan S.E. Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging. Am J Pediatr Hematol Oncol. 15:1993;162.
46. Dusenbery K.E., Steinbuch M., McGlave P.B., Ramsay N.K., Blazar B.R., Neglia J.P., Litz C., Kersey J.H., Woods W.G. Autologous bone marrow transplantation in acute myeloid leukemia. the University of Minnesota experience Int J Radiat Oncol Biol Phys. 36:1996;335.
47. Yeager A.M. Autologous bone marrow transplantation for acute myeloid leukemia. Forman S.J., Blume K.G., Thomas E.D. Bone marrow transplantation. 1994;Blackwell Scientific Publications, Oxford, UK. 709pp.
48. Gorin NC, Labopin M, Laporte JP, Douay L, Lopez M, Lesage S, Fouillard L, Isnard F, Jouet JP, Bellal N, Perot C, Van Den Akker J, Bauters F, Najman A (1999) The role of marrow doses on engraftment in 229 consecutive patients autografted with mafosfmaide purged marrow at a single institution (in preparation).
49. Burnett A.K., Graham S., Alcorn M. Sustained growth in long term bone marrow culture of AML remission marrow predicts a high probability of remaining relapse free after auto BMT in first complete remission. Exp Hematol. 21:1993;1020a.
50. Giralt S., Escudier S., Kantarjian H., Deisseroth A., Freireich E.J., Anderrson B.S., O'Brien S., Andreef M., Fischer H., Cork A., Hirsch-Ginsberg C., Trujillo J., Stas S., Champlin R.E. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 329:1993;757.
51. Sierra J., Storer B., Hansen J.A., Bjerke J.W., Martin P.J., Petersdorf E.W., Appelbaum F.R., Bryant E., Chauncey T.R., Sale G., Sanders J.E., Storb R., Sullivan K.M., Anasetti C. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia. the effect of leukemic burden, donor HLA matching and marrow cell dose Blood. 89:1997;4226.
52. Rowley S.D., Jones R.J., Piantadosi S.et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute non lymphoblastic leukemia. Blood. 74:1989;501.
53. Fouillard L., Laporte J.P., Labopin M., Lesage S., Isnard F., Douay L., Lopez M., Aoudjhane M., Zunic P., Cheron N., Stachowiack J., Lemonnier M.P., Andreu G., Belkacemi Y., Noel-Walter M.P., Morel P., Fenaux P., Jouet J.P., Bauters F., Najman A., Gorin N.C. Autologous stem cell transplantation for non-Hodgkin's lymphomas. the role of graft purging and radiotherapy post transplantation: results of a retrospective analysis on 120 patients autografted in a single institution J Clin Oncol. 16:1998;2803.
54. Bloomfield C.D., Secker-Walker L.M., Goldman A.I.et al. Six year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Gent Cytogenet. 40:1989;171.
55. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A, on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322.
56. Ferrant A., Labopin M., Frassoni F., Prentice H.G., Cahn J.Y., Blaise D., Reiffers J., Visani G., Sanz M.A., Boogaerts M.A., Lowenberg B., Gorin N.C. Karyotype in acute mtyeloblastic leukemia (AML). prognostic significance for bone marrow transplantation in first remission. An EBMT Study Blood. 90:1997;2931.